Cargando…

1567. Pharmacokinetic/Pharmacodynamic Target Attainment in Adult and Pediatric Patients following Administration of Ceftaroline Fosamil as a 5-Minute Infusion

BACKGROUND: Ceftaroline fosamil is approved in the United States for treating patients ≥2 months old with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, and for similar indications in Europe. The active metabolite, ceftaroline, has in vitro activity ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riccobene, Todd, ScD, T J Carrothers, Knebel, William, Raber, Susan, Chan, Phylinda L S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809530/ http://dx.doi.org/10.1093/ofid/ofz360.1431

Ejemplares similares

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion
por: Riccobene, Todd A., et al.
Publicado: (2021)

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Correction to: Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older
por: Franzese, Richard C., et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
por: Cristinacce, Andrew, et al.
Publicado: (2019)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Ceftaroline Fosamil: A Brief Clinical Review
por: Shirley, Debbie-Ann T., et al.
Publicado: (2013)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
por: Johnson, Leonard B., et al.
Publicado: (2019)

Ceftaroline-fosamil: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application
por: Yim, Juwon, et al.
Publicado: (2016)

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
por: Li, Jianguo, et al.
Publicado: (2018)

Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011)

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
por: Maggiore, Christy, et al.
Publicado: (2015)

809 Contemporary Experience with Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia
por: Johnson, Leonard B, et al.
Publicado: (2014)

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
por: Das, Shampa, et al.
Publicado: (2019)

Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis
por: Sotgiu, Giovanni, et al.
Publicado: (2018)

Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital
por: Álvarez, Alicia Alonso, et al.
Publicado: (2021)

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
por: Torres, Antoní, et al.
Publicado: (2023)

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience
por: Santos, Paul D, et al.
Publicado: (2013)

Ceftaroline Fosamil as an Alternative for a Severe Methicillin-resistant Staphylococcus aureus Infection: A Case Report
por: Jilani, Talha N, et al.
Publicado: (2018)

Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury
por: Faris, Janie, et al.
Publicado: (2015)

679 Ceftaroline Fosamil (CPT-F) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients
por: Kaye, Keith, et al.
Publicado: (2014)

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
por: Carrothers, Timothy J., et al.
Publicado: (2019)

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System
por: Torres, Antoni, et al.
Publicado: (2022)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

Tagebuch (Lebensschreibung) 1536–1567
Publicado: (1977)

Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial
por: Zhuo, Chao, et al.
Publicado: (2022)

Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance
por: Chauzy, Alexia, et al.
Publicado: (2022)

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
por: Cheng, Karen, et al.
Publicado: (2019)

Lighting the Shakespearean stage, 1567-1642 /
por: Graves, R. B., 1946-
Publicado: (2009)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials
por: Wilcox, Mark, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections in Critically Ill Patients: Focus on Novel Infusion Mode
por: Song, Xiangqing, et al.
Publicado: (2022)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus
por: Claeys, Kimberly C., et al.
Publicado: (2019)

Remembering Eliahu de Luna Montalto (1567–1616)
por: Weisz, George M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vr2f689kbjbqa4dhn4tiq1utht